Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
BUSINESS
Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
The Japanese pharma industry is largely in favor of the FY2024 drug pricing reform as a whole, but there is discontent over the cost-effectiveness assessment (CEA) system, according to a recent survey conducted by Jiho. A majority of the respondents…
To read the full story
Related Article
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Japan Generic Makers See Smaller Price Cuts in FY2024: Jiho Survey
March 7, 2024
- Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
March 7, 2024
- Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
BUSINESS
- JRI Urges Reforms in Pricing and Reimbursement to Support Regenerative Medicine Ecosystem
July 18, 2025
- Astellas Partners with KISED to Support Korean Biotech Startups
July 18, 2025
- Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
July 18, 2025
- Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
July 18, 2025
- Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
July 17, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…